• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

由NF-κB和p38丝裂原活化蛋白激酶信号介导的前列腺癌基质中的雄激素受体缺失会破坏基质形态发生素的产生。

AR loss in prostate cancer stroma mediated by NF-κB and p38-MAPK signaling disrupts stromal morphogen production.

作者信息

Tahsin Shekha, Sane Neha S, Cernyar Brent, Jiang Linan, Zohar Yitshak, Lee Benjamin R, Miranti Cindy K

机构信息

Cancer Biology Graduate Interdisciplinary Program, University of Arizona, Tucson, AZ, USA.

Department of Cellular and Molecular Medicine, University of Arizona, Tucson, AZ, USA.

出版信息

Oncogene. 2024 Jun;43(27):2092-2103. doi: 10.1038/s41388-024-03064-7. Epub 2024 May 20.

DOI:10.1038/s41388-024-03064-7
PMID:38769192
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11702291/
Abstract

Androgen Receptor (AR) activity in prostate stroma is required to maintain prostate homeostasis. This is mediated through androgen-dependent induction and secretion of morphogenic factors that drive epithelial cell differentiation. However, stromal AR expression is lost in aggressive prostate cancer. The mechanisms leading to stromal AR loss and morphogen production are unknown. We identified TGFβ1 and TNFα as tumor-secreted factors capable of suppressing AR mRNA and protein expression in prostate stromal fibroblasts. Pharmacological and RNAi approaches identified NF-κB as the major signaling pathway involved in suppressing AR expression by TNFα. In addition, p38α- and p38δ-MAPK were identified as suppressors of AR expression independent of TNFα. Two regions of the AR promoter were responsible for AR suppression through TNFα. FGF10 and Wnt16 were identified as androgen-induced morphogens, whose expression was lost upon TNFα treatment and enhanced upon p38-MAPK inhibition. Wnt16, through non-canonical Jnk signaling, was required for prostate basal epithelial cell survival. These findings indicate that stromal AR loss is mediated by secreted factors within the TME. We identified TNFα/TGFβ as two possible factors, with TNFα mediating its effects through NF-κB or p38-MAPK to suppress AR mRNA transcription. This leads to loss of androgen-regulated stromal morphogens necessary to maintain normal epithelial homeostasis.

摘要

前列腺基质中的雄激素受体(AR)活性对于维持前列腺内环境稳定至关重要。这是通过雄激素依赖性诱导和分泌驱动上皮细胞分化的形态发生因子来介导的。然而,在侵袭性前列腺癌中,基质AR表达会丧失。导致基质AR丧失和形态发生素产生的机制尚不清楚。我们确定转化生长因子β1(TGFβ1)和肿瘤坏死因子α(TNFα)为能够抑制前列腺基质成纤维细胞中AR mRNA和蛋白表达的肿瘤分泌因子。药理学和RNA干扰方法确定核因子κB(NF-κB)是TNFα抑制AR表达所涉及的主要信号通路。此外,p38α和p38δ丝裂原活化蛋白激酶(MAPK)被确定为独立于TNFα的AR表达抑制剂。AR启动子的两个区域负责通过TNFα抑制AR。成纤维细胞生长因子10(FGF10)和Wnt16被确定为雄激素诱导的形态发生素,其表达在TNFα处理后丧失,而在p38丝裂原活化蛋白激酶(p38-MAPK)抑制后增强。Wnt16通过非经典Jnk信号通路,是前列腺基底上皮细胞存活所必需的。这些发现表明,基质AR丧失是由肿瘤微环境中的分泌因子介导的。我们确定TNFα/TGFβ为两个可能的因子,其中TNFα通过NF-κB或p38-MAPK介导其作用以抑制AR mRNA转录。这导致维持正常上皮内环境稳定所需的雄激素调节的基质形态发生素丧失。

相似文献

1
AR loss in prostate cancer stroma mediated by NF-κB and p38-MAPK signaling disrupts stromal morphogen production.由NF-κB和p38丝裂原活化蛋白激酶信号介导的前列腺癌基质中的雄激素受体缺失会破坏基质形态发生素的产生。
Oncogene. 2024 Jun;43(27):2092-2103. doi: 10.1038/s41388-024-03064-7. Epub 2024 May 20.
2
Interplay of nuclear factor-kappaB and B-myb in the negative regulation of androgen receptor expression by tumor necrosis factor alpha.核因子-κB与B-myb在肿瘤坏死因子α对雄激素受体表达的负调控中的相互作用
Mol Endocrinol. 2008 Feb;22(2):273-86. doi: 10.1210/me.2007-0332. Epub 2007 Nov 1.
3
Dual specificity phosphatase 1 expression inversely correlates with NF-κB activity and expression in prostate cancer and promotes apoptosis through a p38 MAPK dependent mechanism.双特异性磷酸酶1的表达与前列腺癌中NF-κB的活性和表达呈负相关,并通过p38丝裂原活化蛋白激酶依赖性机制促进细胞凋亡。
Mol Oncol. 2014 Feb;8(1):27-38. doi: 10.1016/j.molonc.2013.08.012. Epub 2013 Sep 14.
4
NF-κB and androgen receptor variant expression correlate with human BPH progression.核因子-κB与雄激素受体变体表达与人良性前列腺增生进展相关。
Prostate. 2016 Apr;76(5):491-511. doi: 10.1002/pros.23140. Epub 2015 Dec 28.
5
Identification of a negative regulatory cis-element in the enhancer core region of the prostate-specific antigen promoter: implications for intersection of androgen receptor and nuclear factor-kappaB signalling in prostate cancer cells.前列腺特异性抗原启动子增强子核心区域负调控顺式元件的鉴定:对前列腺癌细胞中雄激素受体与核因子-κB信号通路交叉的意义
Biochem J. 2004 Apr 15;379(Pt 2):421-31. doi: 10.1042/BJ20031661.
6
Melatonin Inhibits Androgen Receptor Splice Variant-7 (AR-V7)-Induced Nuclear Factor-Kappa B (NF-κB) Activation and NF-κB Activator-Induced AR-V7 Expression in Prostate Cancer Cells: Potential Implications for the Use of Melatonin in Castration-Resistant Prostate Cancer (CRPC) Therapy.褪黑素抑制雄激素受体剪接变体7(AR-V7)诱导的核因子-κB(NF-κB)激活以及NF-κB激活剂诱导的前列腺癌细胞中AR-V7的表达:褪黑素在去势抵抗性前列腺癌(CRPC)治疗中应用的潜在意义。
Int J Mol Sci. 2017 May 31;18(6):1130. doi: 10.3390/ijms18061130.
7
Soluble factors derived from stroma activated androgen receptor phosphorylation in human prostate LNCaP cells: roles of ERK/MAP kinase.来源于基质的可溶性因子激活人前列腺LNCaP细胞中的雄激素受体磷酸化:细胞外信号调节激酶/丝裂原活化蛋白激酶的作用
Prostate. 2009 Jun 15;69(9):949-55. doi: 10.1002/pros.20944.
8
The nuclear factor-kappaB pathway controls the progression of prostate cancer to androgen-independent growth.核因子-κB信号通路控制前列腺癌向雄激素非依赖生长的进展。
Cancer Res. 2008 Aug 15;68(16):6762-9. doi: 10.1158/0008-5472.CAN-08-0107.
9
NF-kappaB regulates androgen receptor expression and prostate cancer growth.核因子-κB调节雄激素受体表达及前列腺癌生长。
Am J Pathol. 2009 Aug;175(2):489-99. doi: 10.2353/ajpath.2009.080727. Epub 2009 Jul 23.
10
Stress kinase signaling regulates androgen receptor phosphorylation, transcription, and localization.应激激酶信号传导调节雄激素受体的磷酸化、转录和定位。
Mol Endocrinol. 2006 Mar;20(3):503-15. doi: 10.1210/me.2005-0351. Epub 2005 Nov 10.

引用本文的文献

1
Interactions between androgen and IGF1 axes in prostate tumorigenesis.雄激素与胰岛素样生长因子1(IGF1)轴在前列腺肿瘤发生过程中的相互作用。
Nat Rev Urol. 2025 May;22(5):268-275. doi: 10.1038/s41585-024-00942-3. Epub 2024 Oct 7.

本文引用的文献

1
Cancer Cell-Extrinsic Roles for the Androgen Receptor in Prostate Cancer.雄激素受体在前列腺癌中的肿瘤细胞外作用。
Endocrinology. 2023 Apr 17;164(6). doi: 10.1210/endocr/bqad078.
2
Activated fibroblasts in cancer: Perspectives and challenges.癌症中的激活成纤维细胞:观点和挑战。
Cancer Cell. 2023 Mar 13;41(3):434-449. doi: 10.1016/j.ccell.2023.02.015.
3
Stratification of radiosensitive brain metastases based on an actionable S100A9/RAGE resistance mechanism.基于可操作的 S100A9/RAGE 耐药机制对脑转移瘤的放射敏感性进行分层。
Nat Med. 2022 Apr;28(4):752-765. doi: 10.1038/s41591-022-01749-8. Epub 2022 Apr 11.
4
Cancer-associated fibroblast-induced lncRNA UPK1A-AS1 confers platinum resistance in pancreatic cancer via efficient double-strand break repair.癌相关成纤维细胞诱导的长链非编码 RNA UPK1A-AS1 通过有效双链断裂修复赋予胰腺癌铂耐药性。
Oncogene. 2022 Apr;41(16):2372-2389. doi: 10.1038/s41388-022-02253-6. Epub 2022 Mar 9.
5
The Role of Androgen Receptor in Cross Talk Between Stromal Cells and Prostate Cancer Epithelial Cells.雄激素受体在基质细胞与前列腺癌上皮细胞相互作用中的作用
Front Cell Dev Biol. 2021 Oct 6;9:729498. doi: 10.3389/fcell.2021.729498. eCollection 2021.
6
Human stroma and epithelium co-culture in a microfluidic model of a human prostate gland.人前列腺微流控模型中的人基质与上皮共培养。
Biomicrofluidics. 2019 Nov 20;13(6):064116. doi: 10.1063/1.5126714. eCollection 2019 Nov.
7
Prostate Stroma Increases the Viability and Maintains the Branching Phenotype of Human Prostate Organoids.前列腺基质可提高人前列腺类器官的活力并维持其分支表型。
iScience. 2019 Feb 22;12:304-317. doi: 10.1016/j.isci.2019.01.028. Epub 2019 Jan 23.
8
Regulation of FGF10 Signaling in Development and Disease.发育与疾病中FGF10信号通路的调控
Front Genet. 2018 Oct 23;9:500. doi: 10.3389/fgene.2018.00500. eCollection 2018.
9
WNT2 is necessary for normal prostate gland cyto-differentiation and modulates prostate growth in an FGF10 dependent manner.WNT2对于正常前列腺细胞分化是必需的,并以FGF10依赖的方式调节前列腺生长。
Am J Clin Exp Urol. 2018 Aug 20;6(4):154-163. eCollection 2018.
10
Myofibroblast androgen receptor expression determines cell survival in co-cultures of myofibroblasts and prostate cancer cells .肌成纤维细胞雄激素受体的表达决定了肌成纤维细胞与前列腺癌细胞共培养时的细胞存活情况。
Oncotarget. 2018 Apr 10;9(27):19100-19114. doi: 10.18632/oncotarget.24913.